<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">docru</journal-id><journal-title-group><journal-title xml:lang="ru">Доктор.Ру</journal-title><trans-title-group xml:lang="en"><trans-title>Title</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1727-2378</issn><issn pub-type="epub">2713-2994</issn><publisher><publisher-name>ООО "ГК "РУСМЕДИКАЛ"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31550/1727-2378-2023-22-2-32-38</article-id><article-id custom-type="elpub" pub-id-type="custom">docru-226</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ГАСТРОЭНТЕРОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>GASTROENTEROLOGY</subject></subj-group></article-categories><title-group><article-title>Клинические проявления у пациентов с генотипами 1 и 3 вируса гепатита С в зависимости от выраженности фиброза печени</article-title><trans-title-group xml:lang="en"><trans-title>Clinical Manifestations in Patients with Genotypes 1 and 3 of Viral Hepatitis C, Depending on the Severity of Liver Fibrosis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черепнин</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Cherepnin</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Черепнин Михаил Александрович — младший научный сотрудник клинического отделения патологии пищеварительной системы у взрослых и детей ФИЦ КНЦ СО РАН НИИ МПС.</p><p>660022, Красноярск, ул. Партизана Железняка, д. 3г</p></bio><bio xml:lang="en"><p>3 G, Partizana Zeleznyaka street, Krasnoyarsk, 660022</p></bio><email xlink:type="simple">mikhail.cherepnin@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9980-2294</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Цуканов</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tsukanov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Цуканов Владислав Владимирович — д. м. н., профессор, заведующий клиническим отделением патологии пищеварительной системы у взрослых и детей ФИЦ КНЦ СО РАН НИИ МПС.</p><p>660022, Красноярск, ул. Партизана Железняка, д. 3г</p></bio><bio xml:lang="en"><p>3 G, Partizana Zeleznyaka street, Krasnoyarsk, 660022</p></bio><email xlink:type="simple">gastro@impn.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5829-672X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Савченко</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Savchenko</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Савченко Андрей Анатольевич — д. м. н., профессор, заведующий лабораторией клеточно-молекулярной физиологии и патологии ФИЦ КНЦ СО РАН НИИ МПС.</p><p>660022, Красноярск, ул. Партизана Железняка, д. 3г</p></bio><bio xml:lang="en"><p>3 G, Partizana Zeleznyaka street, Krasnoyarsk, 660022</p></bio><email xlink:type="simple">aasavchenko@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6481-3196</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Васютин</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vasyutin</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Васютин Александр Викторович — к. м. н., старший научный сотрудник клинического отделения патологии пищеварительной системы у взрослых и детей ФИЦ КНЦ СО РАН НИИ МПС.</p><p>660022, Красноярск, ул. Партизана Железняка, д. 3г</p></bio><bio xml:lang="en"><p>3 G, Partizana Zeleznyaka street, Krasnoyarsk, 660022</p></bio><email xlink:type="simple">alexander@kraslan.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7518-1895</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тонких</surname><given-names>Ю. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Tonkikh</surname><given-names>Yu. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тонких Юлия Леонгардовна — к. м. н., ведущий научный сотрудник клинического отделения патологии пищеварительной системы у взрослых и детей ФИЦ КНЦ СО РАН НИИ МПС.</p><p>660022, Красноярск, ул. Партизана Железняка, д. 3г</p></bio><bio xml:lang="en"><p>3 G, Partizana Zeleznyaka street, Krasnoyarsk, 660022</p></bio><email xlink:type="simple">tjulia@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9026-2615</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Борисов</surname><given-names>А. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Borisov</surname><given-names>A. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Борисов Александр Геннадьевич — к. м. н., ведущий научный сотрудник лаборатории клеточно-молекулярной физиологии и патологии ФИЦ КНЦ СО РАН НИИ МПС.</p><p>660022, Красноярск, ул. Партизана Железняка, д. 3г</p></bio><bio xml:lang="en"><p>3 G, Partizana Zeleznyaka street, Krasnoyarsk, 660022</p></bio><email xlink:type="simple">2410454@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт медицинских проблем Севера — обособленное подразделение ФГБНУ «Федеральный исследовательский центр «Красноярский научный центр Сибирского отделения Российской академии наук»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Scientific Research Institute of Medical Problems of the North — separate division of the Federal Research Centre “Krasnoyarsk Science Centre” of the Siberian Branch of Russian Academy of Science</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>18</day><month>02</month><year>2025</year></pub-date><volume>22</volume><issue>2</issue><issue-title>ТЕРАПИЯ</issue-title><fpage>32</fpage><lpage>38</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Черепнин М.А., Цуканов В.В., Савченко А.А., Васютин А.В., Тонких Ю.Л., Борисов А.Г., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Черепнин М.А., Цуканов В.В., Савченко А.А., Васютин А.В., Тонких Ю.Л., Борисов А.Г.</copyright-holder><copyright-holder xml:lang="en">Cherepnin M.A., Tsukanov V.V., Savchenko A.A., Vasyutin A.V., Tonkikh Y.L., Borisov A.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://docru.elpub.ru/jour/article/view/226">https://docru.elpub.ru/jour/article/view/226</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования: сопоставить клинические проявления у пациентов с генотипами 1 и 3 вирусного гепатита С (HCV) в зависимости от выраженности фиброза печени (ФП).</p></sec><sec><title>Дизайн</title><p>Дизайн: сравнительное исследование случайных групп пациентов, находившихся на стационарном или амбулаторном лечении.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Всего было обследовано 297 больных с генотипом 1 HCV и 231 пациент с генотипом 3 HCV. Диагноз хронического вирусного гепатита С устанавливали по рекомендациям Европейской ассоциации по изучению печени. Всем пациентам выполняли клинический и биохимический анализы крови, ультразвуковое исследование печени и поджелудочной железы. ФП изучали методом сдвиговолновой транзиторной эластометрии с оценкой по шкале METAVIR.</p></sec><sec><title>Результаты</title><p>Результаты. Выраженный ФП был ассоциирован в обеих группах пациентов с увеличением частоты печёночных жалоб, гепатомегалии и спленомегалии, увеличением содержания билирубина и аланинаминотрансферазы в крови, снижением количества тромбоцитов и концентрации альбумина в крови. Только у пациентов с генотипом 3 HCV определялись повышение вирусной нагрузки и тенденция к снижению доли нейтрофилов в крови у лиц с 3–4 стадией ФП в сравнении с 0–2 стадией ФП по METAVIR.</p></sec><sec><title>Заключение</title><p>Заключение. Мы полагаем, что объяснение более высокой частоты выраженного ФП у больных с генотипом 3 HCV, вероятно, заключается в более значительной деформации иммунного ответа, приводящего к увеличению вирусной нагрузки и агрессивному течению патологии.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim: to compare the clinical manifestations in patients with genotypes 1 and 3 of viral hepatitis C (HCV) depending on the severity of liver fibrosis (LF).</p></sec><sec><title>Study Design</title><p>Study Design: a comparative study of randomized groups of patients treated in an inpatient or outpatient setting.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. A total of 297 patients with HCV genotype 1 and 231 patients with HCV genotype 3 were examined. The diagnosis of chronic viral hepatitis C was established according to the recommendations of the European Association for the Study of the Liver. All patients underwent clinical and biochemical blood tests, ultrasound examination of the liver and pancreas. LF was studied by shear wave transient elastometry with METAVIR score.</p></sec><sec><title>Results</title><p>Results. Severe LF was associated in both groups of patients with an increase in the frequency of liver complaints, hepatomegaly and splenomegaly, an increase in the content of bilirubin and alanine aminotransferase in the blood, a decrease in the number of platelets and the concentration of albumin in the blood. Only in patients with HCV genotype 3 was an increase in viral load and a trend towards a decrease in the proportion of neutrophils in the blood in patients with stages 3–4 LF compared with 0–2 stages of LF according to METAVIR.</p></sec><sec><title>Conclusion</title><p>Conclusion. We think that the explanation for the higher incidence of severe LF in patients with HCV genotype 3 is probably a more significant deformation of the immune response, leading to an increase in viral load and an aggressive course of pathology.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>вирусный гепатит С</kwd><kwd>генотип вируса</kwd><kwd>фиброз печени</kwd><kwd>клинические проявления</kwd></kwd-group><kwd-group xml:lang="en"><kwd>viral hepatitis C</kwd><kwd>virus genotype</kwd><kwd>liver fibrosis</kwd><kwd>clinical manifestations</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol. Hepatol. 2022;7(5):396–415. DOI: 10.1016/S2468-1253(21)00472-6</mixed-citation><mixed-citation xml:lang="en">Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol. Hepatol. 2022;7(5):396–415. DOI: 10.1016/S2468-1253(21)00472-6</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ghany M.G., Morgan T.R.; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71(2):686–721. DOI: 10.1002/hep.31060</mixed-citation><mixed-citation xml:lang="en">Ghany M.G., Morgan T.R.; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71(2):686–721. DOI: 10.1002/hep.31060</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Younossi Z., Papatheodoridis G., Cacoub P. et al. The comprehensive outcomes of hepatitis C virus infection: a multi-faceted chronic disease. J. Viral. Hepat. 2018;25(Suppl. 3):6–14. DOI: 10.1111/jvh.13005</mixed-citation><mixed-citation xml:lang="en">Younossi Z., Papatheodoridis G., Cacoub P. et al. The comprehensive outcomes of hepatitis C virus infection: a multi-faceted chronic disease. J. Viral. Hepat. 2018;25(Suppl. 3):6–14. DOI: 10.1111/jvh.13005</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Borgia S.M., Hedskog C., Parhy B. et al. Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes. J. Infect. Dis. 2018;218(11):1722–1729. DOI: 10.1093/infdis/jiy401</mixed-citation><mixed-citation xml:lang="en">Borgia S.M., Hedskog C., Parhy B. et al. Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes. J. Infect. Dis. 2018;218(11):1722–1729. DOI: 10.1093/infdis/jiy401</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ge D., Fellay J., Thompson A.J. et al. Genetic variation in IL28B predicts hepatitisC treatment-inducedviralclearance.Nature.2009;461(7262):399–401. DOI: 10.1038/nature08309</mixed-citation><mixed-citation xml:lang="en">Ge D., Fellay J., Thompson A.J. et al. Genetic variation in IL28B predicts hepatitisC treatment-inducedviralclearance.Nature.2009;461(7262):399–401. DOI: 10.1038/nature08309</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Thrift A.P., El-Serag H.B., Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat. Rev. Gastroenterol. Hepatol. 2017;14(2):122–132. DOI: 10.1038/nrgastro.2016.176</mixed-citation><mixed-citation xml:lang="en">Thrift A.P., El-Serag H.B., Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat. Rev. Gastroenterol. Hepatol. 2017;14(2):122–132. DOI: 10.1038/nrgastro.2016.176</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Бацких С.Н., Морозов С.В., Чуланов В.П., Покровский В.И. Вирус гепатита С 3-го генотипа: такой «простой», такой «сложный». Терапевтический архив. 2012;84(11):4–10.</mixed-citation><mixed-citation xml:lang="en">Batskikh S.N., Morozov S.V., Chulanov V.P., Pokrovsky V.I. Hepatitis C virus genotype 3: that simple, yet that complex. Terapevticheskiy arkhiv. 2012;84(11):4–10. (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Silini E., Bono F., Cividini A. et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology. 1995;21(2):285–290. DOI: 10.1002/hep.1840210204</mixed-citation><mixed-citation xml:lang="en">Silini E., Bono F., Cividini A. et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology. 1995;21(2):285–290. DOI: 10.1002/hep.1840210204</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Щаницына С.Е., Бурневич Э.З., Никулкина Е.Н. и др. Факторы риска неблагоприятного прогноза хронического гепатита С. Терапевтический архив. 2019;91(2):59–66. DOI: 10.26442/00403660.2019.02.000082</mixed-citation><mixed-citation xml:lang="en">Shchanitcyna S.E., Burnevich E.Z., Nikulkina E.N. et al. Risk factors of unfavorable prognosis of chronic hepatitis C. Terapevticheskiy arkhiv. 2019;91(2):59–66. (in Russian). DOI: 10.26442/00403660.2019.02.000082</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Shahnazarian V., Ramai D., Reddy M., Mohanty S. Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges. Ann. Gastroenterol. 2018;31(5):541–551. DOI: 10.20524/aog.2018.0281</mixed-citation><mixed-citation xml:lang="en">Shahnazarian V., Ramai D., Reddy M., Mohanty S. Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges. Ann. Gastroenterol. 2018;31(5):541–551. DOI: 10.20524/aog.2018.0281</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J. Hepatol. 2017;66(1):153–194. DOI: 10.1016/j.jhep.2016.09.001</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J. Hepatol. 2017;66(1):153–194. DOI: 10.1016/j.jhep.2016.09.001</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol. 2018;69(2):461–511. DOI: 10.1016/j.jhep.2018.03.026</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol. 2018;69(2):461–511. DOI: 10.1016/j.jhep.2018.03.026</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ludwig J. Terminology of chronic hepatitis, hepatic allograft rejection, and nodular lesions of the liver: summary of recommendations developed by an international working party, supported by the World Congresses of Gastroenterology, Los Angeles, 1994. Am. J. Gastroenterol. 1994;89(8 Suppl.):S177-S181.</mixed-citation><mixed-citation xml:lang="en">Ludwig J. Terminology of chronic hepatitis, hepatic allograft rejection, and nodular lesions of the liver: summary of recommendations developed by an international working party, supported by the World Congresses of Gastroenterology, Los Angeles, 1994. Am. J. Gastroenterol. 1994;89(8 Suppl.):S177-S181.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349(9055):825–832. DOI: 10.1016/s0140-6736(96)07642-8</mixed-citation><mixed-citation xml:lang="en">Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349(9055):825–832. DOI: 10.1016/s0140-6736(96)07642-8</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Hayes C.N., Imamura M., Tanaka J., Chayama K. Road to elimination of HCV: Clinical challenges in HCV management. Liver Int. 2022;42(9):1935–1944. DOI: 10.1111/liv.15150</mixed-citation><mixed-citation xml:lang="en">Hayes C.N., Imamura M., Tanaka J., Chayama K. Road to elimination of HCV: Clinical challenges in HCV management. Liver Int. 2022;42(9):1935–1944. DOI: 10.1111/liv.15150</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Isakov V., Nikityuk D. Elimination of HCV in Russia: Barriers and Perspective. Viruses. 2022;14(4):790. DOI: 10.3390/v14040790</mixed-citation><mixed-citation xml:lang="en">Isakov V., Nikityuk D. Elimination of HCV in Russia: Barriers and Perspective. Viruses. 2022;14(4):790. DOI: 10.3390/v14040790</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Russo F.P., Zanetto A., Pinto E. et al. Hepatocellular carcinoma in chronic viral hepatitis: where do we stand? Int. J. Mol. Sci. 2022;23(1):500. DOI: 10.3390/ijms23010500</mixed-citation><mixed-citation xml:lang="en">Russo F.P., Zanetto A., Pinto E. et al. Hepatocellular carcinoma in chronic viral hepatitis: where do we stand? Int. J. Mol. Sci. 2022;23(1):500. DOI: 10.3390/ijms23010500</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Singal A.G., Lampertico P., Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J. Hepatol. 2020;72(2):250–261. DOI: 10.1016/j.jhep.2019.08.025</mixed-citation><mixed-citation xml:lang="en">Singal A.G., Lampertico P., Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J. Hepatol. 2020;72(2):250–261. DOI: 10.1016/j.jhep.2019.08.025</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">McGlynn K.A., Petrick J.L., El-Serag H.B. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73 (Suppl. 1):4–13. DOI: 10.1002/hep.31288</mixed-citation><mixed-citation xml:lang="en">McGlynn K.A., Petrick J.L., El-Serag H.B. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73 (Suppl. 1):4–13. DOI: 10.1002/hep.31288</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ahumada A., Rayón L., Usón C. et al. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long? World J. Gastroenterol. 2021;27(40):6737–6749. DOI: 10.3748/wjg.v27.i40.6737</mixed-citation><mixed-citation xml:lang="en">Ahumada A., Rayón L., Usón C. et al. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long? World J. Gastroenterol. 2021;27(40):6737–6749. DOI: 10.3748/wjg.v27.i40.6737</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Zhuang L., Li J., Zhang Y. et al. Real-world effectiveness of direct-acting antiviral regimens against Hepatitis C Virus (HCV) genotype 3 infection: a systematic review and meta-analysis. Ann. Hepatol. 2021;23:100268. DOI: 10.1016/j.aohep.2020.09.012</mixed-citation><mixed-citation xml:lang="en">Zhuang L., Li J., Zhang Y. et al. Real-world effectiveness of direct-acting antiviral regimens against Hepatitis C Virus (HCV) genotype 3 infection: a systematic review and meta-analysis. Ann. Hepatol. 2021;23:100268. DOI: 10.1016/j.aohep.2020.09.012</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Probst A., Dang T., Bochud M. et al. Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis. J. Viral. Hepat. 2011;18(11):745–759. DOI: 10.1111/j.1365-2893.2011.01481.x</mixed-citation><mixed-citation xml:lang="en">Probst A., Dang T., Bochud M. et al. Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis. J. Viral. Hepat. 2011;18(11):745–759. DOI: 10.1111/j.1365-2893.2011.01481.x</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Elsheikh M.E.A., McClure C.P., Tarr A.W., Irving W.L. Sero-reactivity to three distinct regions within the hepatitis C virus alternative reading frame protein (ARFP/core+1) in patients with chronic HCV genotype-3 infection. J. Gen. Virol. 2022;103(3):001727. DOI: 10.1099/jgv.0.001727</mixed-citation><mixed-citation xml:lang="en">Elsheikh M.E.A., McClure C.P., Tarr A.W., Irving W.L. Sero-reactivity to three distinct regions within the hepatitis C virus alternative reading frame protein (ARFP/core+1) in patients with chronic HCV genotype-3 infection. J. Gen. Virol. 2022;103(3):001727. DOI: 10.1099/jgv.0.001727</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Abulitifu Y., Lian J., Adilijiang M. et al. Effectiveness and safety of sofosbuvir-velpatasvir in patients with cirrhosis associated with genotype 3 hepatitis C infection in Xinjiang, China. Infect. Drug. Resist. 2022;15:6463–6470. DOI: 10.2147/IDR.S385071</mixed-citation><mixed-citation xml:lang="en">Abulitifu Y., Lian J., Adilijiang M. et al. Effectiveness and safety of sofosbuvir-velpatasvir in patients with cirrhosis associated with genotype 3 hepatitis C infection in Xinjiang, China. Infect. Drug. Resist. 2022;15:6463–6470. DOI: 10.2147/IDR.S385071</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Loo J.H., Xu W.X.F., Low J.T. et al. Efficacy and safety of sofosbuvir/ velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: a meta-analysis. World J. Hepatol. 2022;14(6):1248–1257. DOI: 10.4254/wjh.v14.i6.1248</mixed-citation><mixed-citation xml:lang="en">Loo J.H., Xu W.X.F., Low J.T. et al. Efficacy and safety of sofosbuvir/ velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: a meta-analysis. World J. Hepatol. 2022;14(6):1248–1257. DOI: 10.4254/wjh.v14.i6.1248</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">McCombs J., Matsuda T., Tonnu-Mihara I. et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern. Med. 2014;174(2):204–212. DOI: 10.1001/jamainternmed.2013.12505</mixed-citation><mixed-citation xml:lang="en">McCombs J., Matsuda T., Tonnu-Mihara I. et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern. Med. 2014;174(2):204–212. DOI: 10.1001/jamainternmed.2013.12505</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Wu N., Rao H.Y., Yang W.B. et al. Impact of hepatitis C virus genotype 3 on liver disease progression in a Chinese national cohort. Chin. Med. J. (Engl). 2020;133(3):253–261. DOI: 10.1097/CM9.0000000000000629</mixed-citation><mixed-citation xml:lang="en">Wu N., Rao H.Y., Yang W.B. et al. Impact of hepatitis C virus genotype 3 on liver disease progression in a Chinese national cohort. Chin. Med. J. (Engl). 2020;133(3):253–261. DOI: 10.1097/CM9.0000000000000629</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
